secwatch.observer — SEC 8-K summary
======================================

Issuer:     Relay Therapeutics, Inc. (RLAY)
CIK:        0001812364
Form:       8-K
Filed at:   2026-05-19T12:45:19+00:00
Accession:  0001193125-26-229770
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Relay Therapeutics Announces Initial Phase 2 Data for Zovegalisib in Vascular Anomalies Showing 60% Response Rate
--------------------------------------------------------------------------------

- 60% of 20 evaluable patients achieved a volumetric response by BICR at first MRI in Phase 2 ReInspire trial; 95% experienced lesion reduction.
- 89% of patients showed clinical improvement per investigator global impression at week 12; 79% per patient global impression.
- Among 22 patients at 100mg and 300mg BID, no dose discontinuations; 9% had Grade 3+ TRAEs; no rash or stomatitis observed.
- Expansion cohorts opened at 400mg QD and 300mg BID for adults/adolescents; pediatric dose-finding ongoing.
- All 32 enrolled patients remained on treatment as of April 15, 2026 data cut-off; prior alpelisib/sirolimus use in 72%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1812364/000119312526229770/0001193125-26-229770-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1812364/000119312526229770/rlay-20260519.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-229770

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer